An observational study in Erdheim-Chester Disease (ECD), sponsored by Meyer Children's Hospital IRCCS. Recruiting at 7 sites in 4 countries. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Meyer Children's Hospital IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Erdheim-Chester Disease with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Erdheim-Chester Disease · United States.
Among the 15 studies in Erdheim-Chester Disease with a site in United States, this one is the only one that started in 2024, is one of 8 observational ones, and was the 15th registered.
22 studies on the registry are indexed under Erdheim-Chester Disease; 11 are open to participants now.
Browse Erdheim-Chester Disease studies →7 of the 15 studies in Erdheim-Chester Disease with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 0–89
Carl Allen · Sites in United States
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Erdheim-Chester Disease studies recruiting now, 8 (73%) set no upper age limit and 1 (9%) stops at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 7 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4
First in 2011; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 37 across the 7 interventional studies, 325 across the 8 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
Meyer Children's Hospital IRCCS is the lead sponsor of 79 studies on the registry; 56 are open to participants now.
Meyer Children's Hospital IRCCS has 2 studies filed under Erdheim-Chester Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Erdheim-Chester Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03990428Memorial Sloan Kettering Cancer CenterSupportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases | 2027-06 |
| NCT05915208University of Alabama at BirminghamHistiocytic Disorder Follow-up Study | 2027-07 |
| NCT05093335Memorial Sloan Kettering Cancer CenterIn-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | 2027-10 |
| NCT03329274Memorial Sloan Kettering Cancer CenterRegistry for Patients With Erdheim-Chester Disease and Other Histiocytoses | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Erdheim-Chester Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis that primarily affects adults but may also occur in pediatric patients. It is characterized by the accumulation of foamy histiocytes with a distinctive immunophenotype in multiple anatomical sites, most commonly the long bones, retroperitoneal and perirenal tissues, the heart, the central nervous system, and the pituitary gland. The disease shows marked clinical heterogeneity, ranging from localized and asymptomatic forms to severe manifestations with multiorgan involvement. From a pathogenetic perspective, ECD is mainly driven by gain-of-function mutations affecting the MAPK and PI3K-AKT pathways, particularly the BRAFV600E mutation, leading to aberrant activation of the MAPK and mTOR signaling pathways. The release of pro-inflammatory cytokines and chemokines plays a key role in systemic inflammation and tissue damage, resulting in significant complications and disability depending on the organs involved.
Despite the significant efforts of international research in recent years, particularly given the extreme rarity of the disease (incidence below 5 cases per 10,000,000 adults per year), substantial knowledge gaps remain, especially with regard to the prediction of long-term outcomes, both in terms of survival and disability. Although some prognostic factors associated with survival have already been identified (such as central nervous system involvement), to date only limited-scale studies have systematically evaluated the prognosis of patients with ECD, focusing in particular on factors influencing organ-specific complications. Moreover, in clinical practice, several aspects that significantly affect patients' quality of life tend to be underestimated, partly due to the time required to perform comprehensive assessments using detailed questionnaires designed to quantify disease-related consequences, such as chronic disability, depression, and cognitive impairment. Nevertheless, there is a growing need for and interest in these parameters, commonly referred to as patient-reported outcomes. In light of these considerations, the development and implementation of a comprehensive prognostic score aimed at predicting survival and long-term disease outcomes could improve the overall assessment of patients and provide more accurate and clinically meaningful prognostic information.
Patients with ECD will be recruited and will attend outpatient visits at the study coordination center at the Meyer IRCCS University Hospital (Florence) and other participating centers. The patients to be enrolled will be "prevalent" and "incident" patients during the 5-year study period. Patients undergoing follow-up at their respective centers will be involved in the study, as well as those who receive a new diagnosis of ECD during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ECD will be recruited and will attend outpatient visits at the study coordination center at the Meyer IRCCS University Hospital (Florence) and other participating centers. The patients to be enrolled will be "prevalent" and "incident" patients during the 5-year study period. Patients undergoing follow-up at their respective centers will be involved in the study, as well as those who receive a new diagnosis of ECD during the study period. Clinical data will be collected from all patients included, focusing primarily on organ involvement and response to treatment. They will also be asked to complete questionnaires on quality of life and other specific outcomes. Epidemiological data will also be considered, in particular the geographical origin of patients, and survival rates will also be evaluated.
Overall survival
The time from the patient's enrollment in the study until death or the last available follow-up
Time frame: 5 years
Association between belonging to a clinical cluster and survival
Clinical cluster of ECD
Time frame: 5 years
Association between organ damage and survival
organ damage related to the disease (e.g., chronic kidney failure)
Time frame: 5 years
Association between the treatment used (relative to the historical period) and survival
treatment received
Time frame: 5 years
Association between response to treatment and survival
complete response rate, partial response, stable disease, progression
Time frame: 5 years
Association between treatment toxicity and survival
incidence and severity of adverse events (classified according to CTCAE v6.0)
Time frame: 5 years
Association between comorbidities and survival
presence of malignant tumors and other chronic diseases
Time frame: 5 years
Association between geographical origin and survival
geographical origin
Time frame: at enrollment
Incidence of comorbidities secondary to the disease or treatment (e.g., secondary malignancies)
To assess the incidence of organ damage related to the disease or comorbidities secondary to the disease or the treatment received
Time frame: 5 years
Association between disease and quality of life
Assessment of the impact on quality of life following disease diagnosis and in response to treatment, using validated questionnaires
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jun 2028, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meyer Children's Hospital IRCCS